The global humanized mouse model market size is projected to be worth USD 101.5 million in 2023. The humanized mouse model market forecasts growth from 2023 to 2033 of 5.8% CAGR to reach USD 178.3 million.
One of the main drivers of increased research activities in humanized mouse models is the rising demand from the healthcare sector for more thorough screening of novel drug candidates discovered to treat various chronic diseases such as cardiovascular conditions, diabetes, and cancers. From 2017 to 2022, the global humanized mouse and rat model market experienced a CAGR of 5.3%.
Key Market Highlights
| Attributes | Details |
|---|---|
| Humanized Mouse Model Market Value for 2023 | USD 101.5 million |
| Humanized Mouse Model Market Value for 2033 | USD 178.3 million |
| Humanized Mouse Model Market CAGR from 2023 to 2033 | 5.8% |
Explore FMI!
Book a free demo
The humanized mouse model demand increased steadily between 2017 and 2022, accelerated by increased research into infectious illnesses, cancer, and immunology. These models were frequently utilized by academic institutions and pharmaceutical corporations for preclinical research, creating a stable humanized mouse model market.
| Historical CAGR | 5.3% |
|---|---|
| Forecast CAGR | 5.8% |
The humanized mouse and rat model market is expected to strengthen significantly between 2023 and 2033. The introduction of customized medicine, increased investment in drug research, and an increasing focus on precision medicines are just a few of the factors that have contributed to this surge. The adoption is fueled by the need for trustworthy preclinical models replicating human physiology.
The humanized mice model market is anticipated to have significant expansion, which reflects the dynamic environment of biomedical research and medication development. Several genes have been discovered in humans but have not been discovered in their orthologous mouse counterparts.
These genetically humanized mice can offer more trustworthy in vivo information regarding human gene function in healthy physiology and disease. As a result, creating genetically modified mice that express an orthologous human gene is becoming increasingly popular.
DRIVERS
RESTRAINTS
OPPORTUNITY
CHALLENGES
Individual biomarkers are used to customize therapies in precision medicine, also known as personalized medicine. Researchers used mice to generate a PDX model for cancer by injecting immune-compromised mice with patient tumor components. Every mouse undergoes a different course of treatment, shaping patients' distinctive tumor-reduction plans.
The demand for individualized medication is set to rise with the adoption of humanized mouse models. Acute myeloid leukemia (AML) and bladder, breast, lung, pancreatic, and ovarian malignancies are just a handful of the illnesses for which Jackson Laboratory has developed more than 450 different PDX oncology mice models.
As a result of advancements in scientific research, associated tools, and technologies, customized medicine has advanced more quickly. These factors are anticipated to fuel humanized mouse model market expansion during the upcoming years.
Humanized mouse models play an integral part in discovering new drugs by providing a crucial link between laboratory research and clinical trials. These models closely resemble how people react to medications because they have immune systems and genetic makeup similar to humans. This allows researchers to evaluate the safety and efficacy of new treatments during the preclinical stages with more accuracy.
This accuracy lowers the possibility of negative outcomes in subsequent clinical studies, saving time and dollars for pharmaceutical companies. The humanized mouse model market stands to gain greatly due to the continued need for better preclinical models to advance drug development pipelines. These models are crucial in the ongoing search for safer and more potent medications.
Researchers are searching for alternatives to conventional models for human study due to increasing humanized mouse model demand from animal rights organizations to discontinue using animals for experimentation. The use of animals for testing has drawbacks, such as the demand for specialized personnel, protracted protocols, and expensive expenses. The study of diabetes uses various methods and non-traditional species, such as rapid computer simulations, artificial blood vessel testing systems, and cell culture techniques for medication investigation.
In vitro testing techniques, online patient drug registries, simulating virtual drug trials, non-invasive imaging techniques including magnetic resonance imaging (MRI) and computed tomography (CT) scans, micro-dosing, and other options are some newer possibilities.
The development of these techniques can affect how humanized mouse models are used as researchers attempt to reduce the price of drug testing. Non-animal-tested products may rise due to marketing that positions them as environmentally beneficial. These factors are anticipated to restrain the humanized mouse model market expansion throughout the forecasted period.
It is anticipated that the genetic humanized mouse models segment is going to dominate the market. This dominance is primarily related to the extensive use of genetically humanized mouse models in various experimental investigations, notably when evaluating the efficacy and safety of substances. The growing use of these mouse models to study medication metabolism and disposition boosts the humanized mouse model market revenue growth.
| Leading Segment | Segment Share |
|---|---|
| Genetic Humanized Mice Model | 53.3% |
The significance of the genetically humanized mouse model segment is attributed to its critical contribution to accelerating drug discovery and development. Genetic humanized mouse models continue to be actively utilized by pharmaceutical and biotechnology businesses and research organizations, solidifying their position as the industry's significant source of revenue for experimental analysis and drug development.
Leading the humanized mouse model market expansion is the oncology section, which takes the lead. To understand the biology of cancer, create new treatments, and assess the effectiveness of medications, oncology research mainly relies on humanized mouse models. These models enable more precise and trustworthy preclinical research by simulating the human tumor microenvironment.
| Leading Segment | Segment Share |
|---|---|
| Oncology | 33.2% |
Due to a pressing demand for cutting-edge cancer research and treatment development, the oncology section takes the lead. The demand for humanized mouse models in this research is anticipated to be strong as long as cancer remains a problem for the world's health, promoting advancement and innovation in cancer therapies.
Academic and Research Institutions are the main humanized mouse model demand generators. These organizations are at the bleeding edge of cutting-edge scientific research. They are actively involved in the investigation of numerous diseases, the creation of new medications, and the testing of new therapeutics. The evaluation of innovative treatments and the comprehension of disease mechanisms are made possible using humanized mouse models in preclinical investigations by academic and research institutes.
| Leading Segment | Segment Share |
|---|---|
| Academic & Research Institutes | 43.9% |
Companies in the pharmaceutical and biotechnology industries and contract research organizations considerably contribute to the rat and mouse model market expansion. These organizations use humanized mouse models to speed up drug discovery and development, resulting in faster market entry of safer and more potent pharmaceuticals. The humanized mouse model market’s variety of end-user categories underscores the crucial role that humanized mouse models have played in improving both therapeutic innovation and medical research.
The humanized mouse model market in North America is anticipated to expand significantly. The demand for customized medicine contributes to the trend, and medication development requires using humanized mouse models for preclinical research. Improvements in genetic engineering and genome editing methods have facilitated the creation of humanized mice models that are more precise and pertinent.
| Attributes | Details |
|---|---|
| North America Market Share | 41.4% |
| United States Market Share | 32.6% |
In North America, pharmaceutical firms and academic institutions increasingly use these models to examine human diseases and evaluate potential treatments. The region's strong healthcare system and significant financial commitments to biomedical research play a role in the rat and mouse model market in North America's promising future.
Due to its critical contribution to advancing biomedical research and drug discovery, the European rat and mouse model market has a positive outlook. The adoption of humanized mouse models is being boosted by this region's dedication to cutting-edge research and healthcare innovation, allowing for more precise disease modeling and preclinical testing. Developments in gene editing technologies have significantly enhanced the accuracy and applicability of these models.
| Attributes | Details |
|---|---|
| Europe Market Share | 33.4% |
| Germany Market Share | 7.9% |
| United Kingdom Market CAGR | 5.9% |
Humanized mouse models are used more frequently by European pharmaceutical corporations and academic institutions to study diseases, assess prospective treatments, and create customized medicine methods. The European humanized mouse model market benefits from a strong healthcare infrastructure and significant investments in the life sciences industry, strengthening its position as a center for creating humanized mouse models.
The Asia Pacific humanized mouse model market is expected to grow rapidly in the future years. The region's booming pharmaceutical and biotechnology companies and a growing emphasis on precision medicine are propelling the use of humanized mouse models for preclinical research. Advances in genetic engineering and genome editing techniques have created more sophisticated and relevant models, increasing their utility in disease modeling and medication testing.
| Attributes | Details |
|---|---|
| India Market CAGR | 5.8% |
| China Market CAGR | 7.0% |
| Japan Market Share | 4.1% |
In Asia Pacific, academic institutions, research organizations, and pharmaceutical corporations progressively incorporate these models into their research workflows. The Asia Pacific is emerging as a leading global humanized mouse model market player. It has substantial potential for innovation and scientific development due to a growing healthcare infrastructure and increased investments in life sciences.
Due to the rising need for preclinical research tools in immunology and drug development, the humanized mouse model industry has a dynamic and varied competitive environment. These businesses use genetic modification methods like CRISPR/Cas9 to create customized mouse models and provide a wide range of humanized mouse models and related services.
Collaborations with pharmaceutical and biotechnology companies for illness modeling and medication testing accelerate competition. Emerging humanized mouse model manufacturers break into the industry, encouraging innovation and healthy competition.
Recent Paradigm Shifts
| Company | Taconic Biosciences |
|---|---|
| Details | The huNOG-EXL EA humanized immune system (HIS) mouse was introduced in January 2022 by Taconic Biosciences, a leader in providing drug research animal model solutions. Taconic's widely utilized HIS portfolio is widened with this offering. The study window in which a myeloid-lineage HIS mouse model can be successfully used is greatly extended by huNOG-EXL EA. |
| Company | genOway |
|---|---|
| Details | Axenis, a firm committed to the creation of immunocompromised models for the validation of novel and innovative therapies, was acquired by genOway, a biotechnology company focused on the design and development of preclinical models, in September 2021. |
| Company | The Jackson Laboratory |
|---|---|
| Details | The Jackson Laboratory (JAX), a nonprofit biomedical research organization, announced in October 2021 that it has acquired the Research Models & Services (RMS) division of Charles River Laboratories Japan as a wholly owned subsidiary. The Jackson Laboratory Japan, a company based in Japan, has about 250 workers, three production facilities in Atsugi, Hino, and Tsukuba, as well as an administrative office in Yokohama. |
Prominent Humanized Mouse Model Manufacturers
The humanized mouse model market to secure a valuation of USD 101.5 million in 2023.
The humanized mouse model market is estimated to reach USD 178.3 million by 2033.
Through 2033, the market is anticipated to expand at a 5.8% CAGR.
From 2017 to 2022, the market recorded a 5.3% HCAGR.
The genetic humanized mice model sector is set to achieve a market share of 53.3%.
A 43.9% mice model market share is expected for the academic & research institutes sector.
The China humanized mouse and rat model market to exhibit a CAGR of 7.0% through 2033.
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Home Healthcare Market Growth - Trends, Innovations & Forecast 2025 to 2035
Catheter Market Insights by Product, Indication, End-user, and Region 2025 to 2035
Healthcare Digital Experience Platform Market Trends - Growth & Forecast 2025 to 2035
Human Growth Hormone (HGH) Treatment and Drugs Market Trends - Growth & Forecast 2025 to 2035
Healthcare Interoperability Solutions Market Analysis – Trends & Growth 2025 to 2035
Humanized Mouse Model Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
